Biopharma Companies – But Not PhRMA – Argue That Mifepristone Ruling ‘Radically Alters’ NDA Process
Executive Summary
BIO signs on while PhRMA and AAM stay on the sidelines as 169 companies, executives and investors file amicus brief supporting FDA’s request for stay of Judge Kacsmaryk’s decision to halt approval of the medication abortion drug. Members of Congress file opposing briefs.
You may also be interested in...
GenBioPro Sues FDA To Keep Generic Mifepristone Available; Supreme Court Delays Its Decision
GenBioPro asks Maryland district court to prevent FDA from taking enforcement actions against it if Supreme Court allows stay of approval of mifepristone. Justice Samuel Alito extends deadline to respond until midnight Friday.
PhRMA Jumps Into Battle Over Mifepristone Regulation With Supreme Court Filing
After sitting out the initial rounds, trade group backs FDA’s decisions on the medication abortion pill and asks Supreme Court to stay Texas district court ruling suspending the drug’s approval.
Fifth Circuit Mifepristone Ruling May Temporarily Halt Pharmacy Dispensing, Generic Approval
Appeals court reverses district court’s stay of FDA’s approval of the medication abortion pill but pauses all agency actions taken since 2016, including changes to REMS and approval of GenBioPro’s generic mifepristone. DOJ and Danco are appealing to the Supreme Court on Friday.